STORM-PE: walking recovery after pulmonary embolism

Why it matters

The October journal publication of STORM-PE’s 90-day follow-up brings functional recovery into the discussion about intervention for intermediate-high-risk pulmonary embolism (PE). ^[1]

For clinical teams, the useful question is whether a treatment changes a person’s recovery enough to justify the resources and risks involved. A favourable scan and a meaningful return to ordinary activity are different outcomes. This update invites services to consider both, without assuming that improvement in one settles every question about the other.

What happened

STORM-PE was an international, open-label randomised trial comparing anticoagulation alone with anticoagulation plus computer-assisted vacuum thrombectomy using the Indigo Aspiration System. Its design specified acute intermediate-high-risk PE with right ventricular dysfunction, an RV/LV diameter ratio of at least 1.0 and elevated cardiac biomarkers. Penumbra funded the study. A blinded independent imaging laboratory assessed the primary endpoint; external event adjudication and an independent safety monitoring board provided additional oversight. ^[2]

Those safeguards matter, but they serve different purposes. Blinded assessment of an image does not make an open-label treatment comparison blinded for participants. Sponsorship should remain visible alongside methodological strengths when clinicians assess how much confidence to place in the findings. ^[2]

What the data show

Among 100 participants at 22 sites, 47 received thrombectomy plus anticoagulation and 53 anticoagulation alone. At 90 days, mean six-minute walking distance was 478.7 versus 368.0 metres (P=0.003). However, only 31/47 and 34/53 completed that test. NYHA class I was recorded in 37/38 versus 34/45 assessed participants (P=0.005). Dyspnoea and quality-of-life scores were comparable, with no reported between-group difference in mortality or symptomatic PE recurrence. These were secondary outcomes; the primary endpoint was RV/LV change at 48 hours. ^[1]

Completeness of follow-up

This is an abstract-based appraisal of the follow-up report, not a full-text methodological review. Missing walking assessments and differing denominators limit how confidently the functional results can be generalised. ^[1]

How it might work

Mechanical removal of obstructing clot aims to relieve acute right ventricular pressure overload. In the earlier STORM-PE report, mean RV/LV improvement at 48 hours was 0.52 with thrombectomy and 0.24 with anticoagulation alone: a difference of 0.27 (95% CI 0.12–0.43; P<0.001). That physiological result supplies context for investigating later recovery, but the imaging measurement is a surrogate outcome. ^[3]

The earlier report also recorded seven-day major adverse events in 4.3% versus 7.5% (P=0.681), with two PE-related deaths in the thrombectomy arm. The trial was powered for RV/LV change, not additional endpoints. Its authors cautioned against extrapolation beyond the studied risk group or to institutions lacking established PE pathways. A nonsignificant safety comparison does not demonstrate equivalence. ^[3]

For readers, the distinction is practical: early relief of cardiac strain offers a biological rationale, while later recovery, procedural harm and survival require their own evidence. None should be used as a substitute for another. ^[3]

Limitations and interpretation

An appropriate reading separates a promising signal from a service-wide decision. Which patients would be eligible locally? What outcome would count as enough benefit to change practice? What missing information could reverse that judgement? These questions encourage scrutiny without dismissing innovation. They also prevent a headline result from becoming a blanket treatment rule.

South African professional implications

The American Heart Association’s official summary of the 2026 multisociety guideline recommends PE response teams and risk-based care. It describes advanced therapies as reasonable for category E1 and potentially appropriate for categories D1–D2. It also emphasises asking about symptoms and functional limitations at every visit for at least a year. These are international recommendations, not confirmation of South African access or reimbursement. ^[4]

For South African services, the editorial priority is a clear pathway: who evaluates deterioration, who participates in intervention decisions, and who tracks recovery after discharge? Local teams could ask whether referral arrangements, procedural expertise, monitoring and follow-up are sufficient before considering any expansion of a service. The evidence discussion should include hospital teams and funders, with patient selection and measurable outcomes specified in advance. No South African regulatory approval, product availability or Aperture distribution relationship is established by this article.

A useful local evaluation would record the reason for treatment selection, the alternative considered and the planned follow-up measures. Its review should ask who is benefiting, who is being excluded and whether the pathway can be sustained outside an initial enthusiastic team.

What to watch

A separate sponsor announcement on 6 October described a STORM-PE wearable substudy presented at VIVA. Daily activity measurements correlated with clinic walking performance, most strongly when wearable and clinic observations were matched around 30 days; associations weakened at 90 days. This was a conference report communicated by the manufacturer. The announcement did not supply correlation coefficients or confidence intervals. ^[5]

“This innovation enables the scientific community to determine whether improvements observed during office assessments are reflected in patients’ real-world experiences at home.” — Robert Lookstein, STORM-PE co-principal investigator, quoted in Penumbra’s sponsor announcement. ^[5]

The next useful evidence would explain whether home activity adds information beyond clinic assessments, how missing wear-time is handled, and whether the participants providing usable device data resemble the wider trial population. A wearable measurement may enrich recovery assessment, but agreement between measurements is not proof that monitoring itself improves outcomes. Independent replication and transparent reporting would help distinguish an interesting research tool from a justified addition to routine care.